Comments
Shares of Aurobindo Pharma surged over 2 per cent today after the company got final approval from USFDA to manufacture and market its generic Naproxen Sodium tablets used for the treatment of osteoporosis.
The stock soared 2.31 per cent to Rs 738 on the BSE. On the NSE too, shares of the company climbed 2.31 per cent to Rs 737.95.
“The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Naproxen Sodium tablets USP, 220 mg,” Aurobindo Pharma had said in a BSE filing on Saturday.
“The product is expected to be launched in Q1 of 2016-17,” it had said.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.